Rogorafenib is a multikinase inhibitor targeting tumor cells, vasculature, angiogenesis, and the tumor microenvironment by blocking the activity of several protein kinases, including those involved in the regulation of angiogenesis (VEGFR-1, VEGFR-2, and VEGFR-3, and TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, and BRAFV600E), and tumor microenvironment (PDGFR and FGFR) [39]. This evidence concerns the gene PDGFRB and neoplasm.